AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed glioblastoma multiforme, meeting 1 of the following criteria: * Phase I * In first or second recurrence or relapse * At least 1 measurable or evaluable enhancing lesion by gadolinium MRI (Gd-MRI) of the brain within the past 3 weeks * Phase II, group 1 * In first or second recurrence or relapse by Gd-MRI of the brain within the past 3 weeks * Requires tumor biopsy OR surgical resection for tumor debulking or for confirmation of recurrence * Phase II, group 2 * In first recurrence or relapse * At least 1 bidimensionally measurable enhancing lesion (≥ 1.5 cm\^2 using product of the largest perpendicular diameters) by Gd-MRI of the brain within the past 3 weeks * Multifocal disease allowed PATIENT CHARACTERISTICS: Performance status * Karnofsky 70-100% Life expectancy * At least 12 weeks Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Hemoglobin ≥ 9 g/dL * Platelet count ≥ 100,000/mm\^3 Hepatic * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN * No acute or chronic liver disease Renal * Total calcium (corrected) normal\* * Creatinine ≤ 1.5 times ULN OR * Creatinine clearance ≥ 50 mL/min * No proteinuria by dipstick OR * Total urinary protein ≤ 500 mg AND creatinine clearance ≥ 50 mL/min by 24-hour urine collection * No acute or chronic renal disease NOTE: \*Supplements allowed Cardiovascular * LVEF ≥ 45% by MUGA or echocardiogram * No complete left bundle branch block * No requirement for a cardiac pacemaker * No congenital long QT syndrome * No ventricular or atrial tachyarrhythmias * No clinically significant resting bradycardia, defined as \< 50 beats per minute * QTc ≤ 480 msec by ECG * No right bundle branch block and left anterior hemiblock (bifascicular block) * No uncontrolled hypertension OR history of labile hypertension * No unstable angina pectoris OR angina pectoris occurrence within the past 3 months * No congestive heart failure * No acute myocardial infarction within the past 3 months * No history of poor compliance with an antihypertensive regimen * No other impaired cardiac function or clinically significant cardiac disease Gastrointestinal * No unresolved diarrhea ≥ grade 2 * No impairment of gastrointestinal (GI) function or GI disease that would significantly alter absorption of study drugs, including any of the following: * Ulcerative disease * Uncontrolled nausea * Vomiting * Malabsorption syndrome Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception * Potassium normal\* * Magnesium normal\* * Phosphorus normal\* * Cholesterol ≤ 300 mg/dL (treatment allowed) * Triglycerides ≤ 2.5 times ULN (treatment allowed) * No known HIV positivity * No peripheral neuropathy ≥ grade 2 * No uncontrolled diabetes * No active or uncontrolled infection * No other severe and/or uncontrolled medical condition that would preclude study participation or compliance * No contraindication to MRI, including any of the following: * Cardiac pacemaker * Ferromagnetic metal implants other than those approved as safe for use with magnetic resonance scanners (e.g., some types of aneurysm clips or shrapnel) * Claustrophobia * Obesity exceeding magnetic resonance equipment limits * No other clinically significant primary malignancy requiring active intervention NOTE: \*Supplements allowed PRIOR CONCURRENT THERAPY: Biologic therapy * More than 2 weeks since prior hematopoietic colony-stimulating factors (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\]) except epoetin alfa * More than 2 weeks since prior immunotherapy and recovered * No concurrent biologic therapy * No concurrent prophylactic hematopoietic growth factors (e.g., G-CSF or GM-CSF) unless approved by the study sponsor Chemotherapy * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered * Prior polifeprosan 20 with carmustine implant (Gliadel® wafer) allowed * No other concurrent chemotherapy Endocrine therapy * Must be on stable or deceasing doses of steroids for at least 7 days before baseline Gd-MRI of the brain and before starting study drug * No concurrent tamoxifen Radiotherapy * More than 4 weeks since prior radiotherapy and recovered * No concurrent radiotherapy Surgery * More than 1 week since prior tumor biopsy * More than 2 weeks since prior surgical resection * More than 2 weeks since prior major non-CNS surgery and recovered * No prior small bowel resection Other * At least 2 weeks since prior and no concurrent enzyme-inducing anticonvulsant drugs * More than 4 weeks since prior investigational drugs and recovered * No prior epidermal growth factor receptor- or ErbB-2-directed therapy (phase II only) * No prior vascular endothelial growth factor (VEGF) or VEGF receptor-directed therapy (phase II only) * No prior mTOR-directed therapy (phase II only) * No concurrent therapeutic warfarin * No concurrent treatment with any medication that may prolong QT interval, including any of the following: * Quinidine * Procainamide * Disopyramide * Amiodarone * Sotalol * Bretylium * Ibutilide * Thioridazine * Mesoridazine * Chlorpromazine * Amitriptyline * Imipramine * Desipramine * Doxepin * Erythromycin * Clarithromycin * Ketoconazole * Halofantrine * Quinine * Chloroquine * Mefloquine * Moxifloxacin * Gatifloxacin * Pimozide * Risperidone * Ziprasidone * Venlafaxine * Maprotiline * Lithium * Pentamidine * Droperidol * Dolasetron * No concurrent digoxin or verapamil * No concurrent tacrolimus * No other concurrent investigational agents